Prostate cancer remains a significant health problem worldwide and is the second highest cause of cancer-related death in men. While there is uncertainty over which men will benefit from radical treatment, considerable efforts are being made to reduce treatment related side-effects and in optimizing outcomes. The current gold standard treatment for localized prostate cancer remains open radical prostatectomy. Since the early 1990s, several teams have tried to explore less invasive surgical access. The first robotically assisted laparoscopic prostatectomy (RALP) case was reported in 2000. Enhancement of the ergonomics and optimization of the surgical vision provided by the robotic interface are some of the reasons that explain the worldwide wide spread of RALP. Although this procedure accounted for the vast majority of radical prostatectomies performed in United States, its diffusion is still limited in Europe. The cost for robot purchase and maintenance are obvious limiting factors for its expansion. According to the literature, the operating time and the blood loss are, once the learning curve is completed, similar to those of open or laparoscopic procedures. Hospital stay and time before bladder catheter removal are shorter compared with other approaches. Intermediate oncologic and functional outcomes do not show difference with the open or laparoscopic results. Given that these data are encouraging, the limited follow-up with RALP does not allow drawing any definitive statement in comparison with conventional techniques. The aim of our study was to underline the perioperative, oncologic, and functional outcomes of all extraperitoneal RALP series published.
Copyright © 2013 Elsevier Inc. All rights reserved.